SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 8, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced today the publication of “real world” data showing that the Afirma® Genomic Sequencing Classifier (GSC) enables even more patients to avoid unnecessary surgery in thyroid cancer diagnosis compared
Revenue Grew 34 Percent and Genomic Test Volume Increased 23 Percent Company Increases Annual Revenue Guidance and Lowers Cash Burn Guidance for 2018 Conference Call and Webcast Today at 4:30 p.m. EDT SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 29, 2018-- Veracyte, Inc.
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 15, 2018-- Veracyte, Inc. (Nasdaq: VCYT) will release its third quarter 2018 financial results after the close of market on Monday, October 29, 2018 . Company management will host a conference call and webcast to discuss financial results and
Preliminary data from ongoing, three-year registry study demonstrate that reduction in potentially harmful invasive procedures extends for first 12 months post-test SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 9, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced that new interim data from a
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 8, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced the presentation of data demonstrating that the Envisia Genomic Classifier can help physicians more confidently diagnose interstitial lung disease (ILD), including idiopathic pulmonary fibrosis
Study findings reported at the American Thyroid Association Annual Meeting SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 6, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced today that new findings from six studies reinforcing the “real world” performance of the next-generation Afirma Genomic
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 27, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, will present at the 2018 Cantor Fitzgerald Global Healthcare Conference on Tuesday, October 2, 2018 , at 1:05 p.m.
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 27, 2018-- Veracyte, Inc. (NASDAQ: VCYT) announced that new data highlighting the ability of the Percepta Bronchial Genomic Classifier to reduce unnecessary invasive procedures in lung cancer diagnosis will be shared in an oral presentation at
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 26, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that findings from six studies will be presented at the 88 th Annual Meeting of the American Thyroid Association (ATA), demonstrating the “real world” performance of the Afirma Genomic
First Test for Improved IPF Diagnosis Receives Draft Local Coverage Determination Through the MolDx Program SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 30, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced that it has received a draft Medicare local coverage determination (LCD) for the Envisia
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.
